Skip to main content

Table 1 Standard therapeutic approach and escalation therapies

From: General principles and escalation options of immunotherapy in autoantibody-associated disorders of the CNS

First-line therapies


1000 mg/day for 5 days, if needed with oral tapering

 Intravenous immunoglobulin

0.4 g/kg/day over 5 days

 Plasma exchange or immunoadsorbtion

5–7 cycles

 +Tumor therapy in paraneoplastic cases as soon as possible!

Escalation immunotherapies§


Initially 500–2000 mg IV, followed by 250–1000 mg every 6 months or depending on B-cell repopulation*


Induction with 750–1000 mg/m2 of BSA (e.g. 300–350 mg/m2/d over 3 days), followed by 500–750 mg/m2 of BSA every 4 weeks#

Further long-term immunotherapies§

 Intravenous immunoglobulin

1 g/kg body weight every 4–6 weeks IV, alternatively subcutaneously in equivalent dose (home setting)

 Oral immunosuppressive drugs alone or in combination with prednisolone


2–3 mg/kg/d


7.5–20 mg/week

 Mycophenolate mofetil

1000–2000 mg/kg/d

Reserve therapies in refractory disease course


8 mg/kg every 4 weeks


1–2 cycles with 1.3 mg/m2/cycle s.c., administered on days 1, 4, 8, 11, followed by other long-term therapy.

  1. §Treatment duration depending on the individual relapse risk in different diseases.
  2. *Consider re-infusion already by beginning repopulation. Intervals can be usually prolonged in case of sustained depletion and clinical stabilization in patients > 50 years old and/or after several years of rituximab therapy
  3. #Absolute dose depends on leucocyte nadir. Due to toxicity a lifetime cumulative dosage is limited. Accordingly intervals can be prolonged or therapy can be switched in case of clinical stabilization.